Atmo Biosciences

About

Atmo Biosciences produces an ingestible vitamin‑sized gas sensor that detects location‑specific GI gases and uploads data to a cloud platform for microbiome function analysis and motility disorder assessment.

Mission

Atmo Biosciences developed a world‑first ingestible gas‑sensing capsule that electronically detects gases at known locations in the gastrointestinal tract and uploads data to a cloud platform for analysis. The capsule is sized like a vitamin pill and is intended to provide direct measurement of microbiome function, offering an alternative to invasive or trial‑and‑error diagnostic approaches. Its first clinical application targets motility disorders, with a pivotal clinical study currently underway in Australia and the United States. Independent research organisations are also using the capsule in trials for conditions including irritable bowel syndrome, inflammatory bowel disease and liver disease. The technology was invented at RMIT University in 2011 and later spun out into Atmo with commercialisation support from Planet Innovation. Breakthrough Victoria has invested in Atmo via a share purchase from Planet Innovation, and the company closed a Series B in February 2023. Atmo is preparing a Series C in 2024 to fund commercialisation and a manufacturing ramp‑up.

Quick Facts